Abiopharma

🔍 Pfann Oliver (Executive)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 642 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,786.68 | transaction_form_type: 4 | Footnotes: F1
• Sold 328 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 3,458.68 | transaction_form_type: 4 | Footnotes: F2
• Acquired 230 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,688.68 | transaction_form_type: 4 | Footnotes: F1
• Sold 118 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 3,570.68 | transaction_form_type: 4 | Footnotes: F2
• Acquired 230 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,800.68 | transaction_form_type: 4 | Footnotes: F3
• Sold 118 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 3,682.68 | transaction_form_type: 4 | Footnotes: F2
• Acquired 642 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 642.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 642 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Acquired 230 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 230.00 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Sold 230 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Acquired 1,123 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,123.00 | transaction_form_type: 4 | Footnotes: F4, F7, F7
• Sold 230 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F8, F8
• Acquired 9,149 shares of Stock Options (right to buy) at $483.62 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: 0 | shares_owned_after: 9,149.00 | transaction_form_type: 4 | Footnotes: F11
• Holds 981 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 981.00 | Footnotes: F4, F9, F9
• Holds 905 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 905.00 | Footnotes: F4, F10, F10
• Holds 6,890 shares of Stock Options (right to buy) at $468.77 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2035-03-07 | shares_owned_after: 6,890.00 | Footnotes: F12
• Holds 5,840 shares of Stock Options (right to buy) at $465.29 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2034-03-07 | shares_owned_after: 5,840.00 | Footnotes: F13
• Holds 1,000 shares of Stock Options (right to buy) at $354.14 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2033-03-07 | shares_owned_after: 1,000.00 | Footnotes: F14
• Holds 620 shares of Stock Options (right to buy) at $270.99 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2032-03-07 | shares_owned_after: 620.00 | Footnotes: F15

Footnotes:

• F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023.
• F2: Ordinary shares withheld from the payout to cover tax withholdings.
• F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit grant made on March 7, 2023.
• F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis.
• F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis.
• F8: Restricted Stock Units that vested in full and paid out on March 9, 2026 in Linde plc Ordinary Shares on a one-for-one basis.
• F9: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis.
• F10: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
• F11: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027.
• F12: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026.
• F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025.
• F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024.
• F15: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2023.